Study registration: *
Publication Chemaitelly H, Nat. Med., 2021
Dates: 2021-02-01 to 2021-05-10
Funding: Public/non profit (Biomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core and the Genomics Core, all at Weill Cornell Medicine–Qatar, Ministry of Public Health and Hamad Medical Corporation, the Qatar Genome Program)
Conflict of interest: no COI (The authors declare no competing interests.)

Methods

Study design:Test-negative
Description of participants: Mainly working-age adults not vaccinated or receiving at least one dose of the mRNA- 1273 vaccine or completed the two-dose regimen
Inclusion criteria:
  • Resident population in Qatar (mainly working-age adults) with PCR-positive or negative for SARS -CoV-2 infection between March 8 and May 10 2021
  • Individuals not vaccinated or receiving at least one dose of the mRNA- 1273 (Moderna)vaccine or completed the two-dose regimen.

Exclusion criteria:
  • Resident population in Qatar that have BNT162b2 vaccination record or being tested using PCR outside the study period (done before March 8 2021).

Follow-up duration (months): 3
Vaccines:
  • 1 / 2 doses of mRNA-1273
Variant description :
Variant name: Alpha
Evidence: Direct evidence (effectiveness determined by sequencing cases)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Yes
Data accessibility: Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default. aspx)
General comment Concerns regarding residual confounding and bias in selection of participants into the study (test-negative design).